Stock Price Quote

BIOCON LTD.

NSE : BIOCONBSE : 532523ISIN CODE : INE376G01013Industry : Pharmaceuticals & DrugsHouse : Private
BSE307.502.8 (+0.92 %)
PREV CLOSE ( ) 304.70
OPEN PRICE ( ) 307.80
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 336390
TODAY'S LOW / HIGH ( )304.10 310.35
52 WK LOW / HIGH ( )217.5 321.3
NSE307.603.05 (+1 %)
PREV CLOSE( ) 304.55
OPEN PRICE ( ) 308.00
BID PRICE (QTY) 307.60 (19)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 4861851
TODAY'S LOW / HIGH( ) 304.05 310.70
52 WK LOW / HIGH ( )217.5 321.2
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 29-11 1978
Management Info
Kiran Mazumdar-Shaw - Chairman Siddharth Mittal - Managing Director
Registered Office

Address 20th Km,Hosur Road,Electronic City,
Bengaluru,
Karnataka-560100

Phone 080 2808 2808

Email corporate.communications@biocon.com

Website www.biocon.com

Registrars Details
K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.)
Karvy Selenium Tower B, Plot 31-32,Gachibowli,Financial District,Nanakramguda,Hyderabad
Listing : BSE, NSE, MCX

NEWS

21May Biocon informs about press release
Biocon has informed that it enclosed the press release titled ‘Biocon Bi..
21May Biocon’s arm gets USFDA’s nod for Yesa
Biocon’s subsidiary -- Biocon Biologics has received U.S. Food and Drug..
21May Biocon rises as its arm gets USFDA’s n
Biocon is currently trading at Rs. 306.40, up by 1.70 points or 0.56% fr..
17May Biocon reports 46% fall in Q4 consolid
Biocon has reported results for fourth quarter (Q4) and year ended March..
17May Biocon rises despite reporting 46% fal
Biocon is currently trading at Rs. 308.50, up by 2.60 points or 0.85% fr..

Financials

in Millions
QTR Mar 24 ANNUAL 24
Net Profit1401193
Gross Profit 218 1503
Operating Profit 9114557
Net Sales 532621273

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Sanofi India (BSE)
peergroup  8931.65 (1.17%)
M.Cap ( in Cr)20672.06
Divi's Lab (BSE)
peergroup  4018.00 (2.33%)
M.Cap ( in Cr)105372.44
NGL Fine-Chem (BSE)
peergroup  2401.25 (2.96%)
M.Cap ( in Cr)1454.15
Gland Pharma (BSE)
peergroup  1802.00 (1.28%)
M.Cap ( in Cr)29372.83
Aurobindo Pharma (BSE)
peergroup  1220.60 (1.49%)
M.Cap ( in Cr)70848.77

Shareholding Pattern

MUTUAL FUNDS/UTI 8.57%
PROMOTERS 60.64%
FI/BANKS/INSURANCE 5.02%
NON-INSTITUTION 20.05%
GOVERNMENT 0%
FII 0%

About

no data found

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.